Publicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (17)

2024

  1. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    The Lancet Haematology, Vol. 11, Núm. 2, pp. e147-e159

  2. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

  2. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

    Frontiers in Immunology, Vol. 14

2021

  1. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 7, pp. 1593-1602

2020

  1. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

    Frontiers in Immunology, Vol. 11

  2. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

    Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 681-694

  3. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (Bone Marrow Transplantation, (2020), 55, 4, (681-694), 10.1038/s41409-019-0718-7)

    Bone Marrow Transplantation

  4. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    The Lancet Haematology, Vol. 7, Núm. 2, pp. e157-e167

  5. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

    Bone Marrow Transplantation, Vol. 55, Núm. 6, pp. 1093-1102

2019

  1. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study

    The Lancet Haematology, Vol. 6, Núm. 2, pp. e89-e99

  2. Haploidentical Stem Cell Transplantation with Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults with Hematologic Cancers: A Systematic Review and Meta-Analysis

    JAMA Oncology, Vol. 5, Núm. 12, pp. 1739-1748

2018

  1. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: A retrospective study on behalf of the chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 53, Núm. 3, pp. 255-263

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Antilymphocyte globulin for prevention of chronic graft-versus-host disease

    New England Journal of Medicine, Vol. 374, Núm. 1, pp. 43-53

  2. The authors reply

    New England Journal of Medicine

2004

  1. Lenograstim after autologous peripheral blood progenitor cell transplantation: Results of a double-blind, randomized trial

    Bone Marrow Transplantation, Vol. 34, Núm. 11, pp. 955-962